Redustim is a class 2a medical device based on an innovative procedure that uses BioMagnetic action to gradually reduce harmful abdominal fat. The 100% hands-free treatment delivers visible results after 12 x 30 minute sessions. ReduStim is suitable for all patients who want to reduce their waist size. Clinical tests show an average reduction of more than 6 cm.

1. 1
Abdominal obesity:
the risks factors
Redustim:
a medical device solution

2. Company Profile
Stéphanie Audran
CEO European Office
PARIS - France

3. Clinical initial proof of
concept
Genetic profiling Finalization of a product portfolio
addressing the needs of aesthetic
and medical professionals
1998 2002 2009 2016
OVER A DECADE OF ADVANCED RESEARCH DEDICATED
TO BIOMAGNETIC STIMULATION HEALTH APPLICATIONS
History

4. In 12 years, our Group becomes a large entity, by developping its worlwide
activities.
Several thousands of professionals were equipped in France and abroad. Well
known beauty centers trusted our technology and are using our devices to better
serve their patients.
Filiale GCC : 4 personnesHead office Paris Training center Paris R&D and Production Tunis Digital office Casablanca GCC office Dubaï
DUBAI OFFICE
A whole group dedicated to fat reduction

5. Developer, manufacturer of medical equipment to reduce health
risks related to abdominal fat.
+15 years at the service of beauty and health industries
professionnals.
BioMagnetic field for a unique lipolytic action.
Non-aggressive, non-invasive with no secondary effect.
Group presentation

6. BEAUTY
FORM
HEALTH
SHAPE
SPORT
OBESITY
OUR GCC TARGET
Various application fields

7. 7
LipiDrainor
BodySculptor exCell+
BodySculptor intégral+
MyoSculptor
OsmoSculpt
Our solutions in the beauty industry

8. BIOMAGNETIC FIELD
+ MICROPRESSURE
BIOMAGNETIC FIELD
Our solutions in the health industry

9. FRANCE
500 equiped centers
Aesthetic sector:
• Beauty centers
• Spas
• Hotels
Health sector:
• Aesthetic Doctors
• Nutritionists & Dietitians
• Cardiologists
• Gynecologists
• Physiotherapists
EXPORT
2000 equiped centers
Created in 2006, the Export department is rapidly
expanding with a presence already in about 15
countries mostly in Europe and Maghreb.
Other Export contracts are in the course of negotiation
on markets with great potential in Emirates thanks to
our subsidiary based in Dubai.
Our distribution network

10. +2500
Equiped
centers
around the
world
Years in the
beauty and
health
industry
Scientific
and
medical
studies
French and
international
patents
+15 +10 +5
Companies
promoting
BioMagnetic
Fields
+5
Nowadays …

11. Abdominal obesity
Context and Risks
Dr Philippe BLANCHEMAISON
Angiologist – Phlebologist
PARIS - France

12. Obesity is rising unrelentingly in all industrialized countries !
Pooled analysis of 1698 population-based measurement studies with
19·2 million participants – source The Lancet.
If post-2000 trends continue, by 2025, global obesity prevalence will
reach 18% in men and surpass 21% in women; severe obesity will
surpass 6% in men and 9% in women.
Obesity and overweight contribute to:
v
CARDIOVASCULAR
DISEASE
DIABETE CANCER
Obesity: the evil of the century

13. Abdominal obesity: the main cause of metabolic syndrome
Abdominal obesity increases hypertension
Abdominal obesity: a cause of cardiovascular disease and stroke
Abdominal obesity: cause of infertility
Big belly = 5 times more likely to have diabetes
Abdominal obesity causes risk of impotence
Abdominal obesity: risks of mortality doubled
Abdominal obesity care of the cirrhosis
Abdominal obesity improve cancer risks
Abdominal obesity: did you know?

14. Abdominal or visceral fat is:
• located in the abdominal cavity
around the organs.
• a very high risk factor for heart
disease and type 2 diabetes.
Abdominal obesity: a source of serious medical complications
Abdominal obesity:
• characterized by a large waist circumference.
• clearly reduces life expectancy.
• numerous complications (high blood pressure, high
cholesterol, heart attack, stroke and certain cancers).
• indicator of visceral fat.

15. Metabolic syndrom
=> Existence of many abnormalities due to abdominal
fat accumulation
Concerned if you have at least 3 of the following
abnormalities:
=> Generally associated with being overweight.
Waist circumference
> 102 cm for men
and > 88 cm for women
Triglycerides
> 1.5 g/l
HDL Cholesterol
< 0.5 g/l for men and
< 0.4 g/l for women
Fasting glucose
> 1 g/l
Blood pressure
> 13/8.5
Criteria and thresholds defined by the WHO and NCEP ATP III

16. Which
therapeutic
strategy against
abdominal
obesity ?
REDUSTIM, THE EFFICIENT
PHYSICAL METHOD
THAT CAN REDUCE UP TO 2
CLOTHING SIZES
WITHOUT PAIN NOR SIDE
EFFECTS.

17. 5 critères d’évaluation du syndrome métabolique

18. AbdominalobesityinGCC
&consequencesforthepopulation
Dr Afra bin KATTA
Head of Nutrition Rashid hosp.
Dubaï Health Autority

19. Dietary and lifestyle recommandation
19
ADRENAL OVARY THYROID LIVER
The 4 new body type

20. General objectives
20
1/ To provide guidelines for health professionals, for the nutritional
management of OBESITY.
2/ To provide the efficacy of a comprehensive lifestyle intervention
program, to facilitating weight loss or maintenance of lost weight.

21. Projected prevalence of overweight, UAE
21

22. Screening assessment
22
Anthropometric Measurements
Description Women Men
Essential fat 10–13% 2–5%
Average 25–31% 18–24%
Obese 32%+ 25%+
Fitness 21–24% 14–17%
Athletes 14–20% 6–13%

23. Anthropometric measurements
23
Disease Risk* Relative to Normal Weight and Waist Circumference
BMI
(kg/m²)
Obesity
Class
Men 102 cm (40 in) or less
Women 88 cm (35 in) or less
Men > 102 cm (40 in)
Women > 88 cm (35 in)
Underweight < 18.5 - -
Normal 18.5–24.9 - -
Overweight 25.0–29.9 Increased High
Obesity 30.0–34.9 I High Very High
Severe Obesity
35.0–39.9 II Very High Very High
Extreme Obesity 40.0 + III Extremely High Extremely High
* Disease risk for type 2 diabetes, hypertension, and CVD.
+ Increased waist circumference also can be a marker for increased risk, even in persons of normal weight.

24. There are various ways of measuring abdo obesity
24
1. Waist Circumference: >102 cm (40 in) in men and >88 cm (35 in) in women
2. Waist–hip Ratio: the circumference of the waist divided by that of the hips of >0.9 for men and >0.85 for women
For example: A waist measurement of (68.6 cm) divided by a hip measurement of (91.4 cm) would calculate to a WHR of
0.75.
3. Waist-to-height Ratio
Formula Waist to height ratio (WHtR) = ( Waist circumference / Height ) x 100
MEN: Ratio less than 35: Abnormally Slim to Underweight-Ratio 35 to 43: Extremely slim-Ratio 43 to 46: Slender and
Healthy-Ratio 46 and 53: Healthy, Normal Weight-Ratio 53 to 58: Overweight-Ratio 58 to 63: Extremely Overweight/Obese-
Ratio over 63: Highly Obese
WOMEN: Ratio less than 35: Abnormally Slim to Underweight-Ratio 35 - 42: Extremely Slim-Ratio 42 to 46: Slender and
Healthy-Ratio 46 to 49: Healthy, Normal Weight-Ratio 49 to 54: Overweight Ratio 54 to 58: Seriously Overweight-Ratio over
58: Highly Obese
4. Sagittal Abdominal Diameter
For persons of normal BMI, SAD should be under 25 centimeters.

25. A multidisciplinary approach …
25
Physical
Therapy
Behaviour
Modification
Medical
Therapy
Surgery
Dietary
Management
… can identify the different factors and engage a program that leads to necessary reduction in weight:

26. Medical therapy
26
Assessing Medication Efficacy and Safety
Effective Ineffective
Loss of ≥5% body weight at 3 months and
medication is safe/tolerated
Loss of <5% body weight at 3 months or safety or
tolerability issue with medication
Continue medication Discontinue medication
Seek alternate medication or refer for alternative
therapy
Source: Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab. 2015.100(2):342–362.

27. Nut intervention goals
27
• Set clear goals with a realistic timescale.
• Start reducing 5-10% from actual body weight
• Address individual needs based on Age, Height, Weight,
Medical history, Cultural, Religious, and preferences….
• Re- evaluate the nutrition intervention.

28. Set clear goals with a realistic timescale
28
START REDUCING 5-10% FROM ACTUAL BODY WEIGHT
• 5-10 percent weight-loss can result in a five point increase in HDL cholesterol.
• Was shown to decrease TG by an average of 40mg/dl.
• Both Systolic/ Diastolic decrease by 5mmHg
• Has effect with diabetes by improve A1C, and Insulin Resistance
• Sleep Apnea

29. Address individual needs
based on Age, Height, Weight, Medical history, Cultural, Religious, and preferences….
29
Energy requirements based on
body weight and activity level
In patients who are not catabolic, energy
requirements based on activity level are often
quite acurate. However, a major limitation of
this system is the absence of a precise
definition of overweight, normal weight, and
underweight, as well as activity level.
Energy requirements based on
body weight and activity level
Age Energy needs, kcal/lb Energy needs, kcal/kg
0-6 months 49 108
6-12 months > 45 > 98
1-10 years 45 to 32* 100 to 70*
Females 11-14 years 21 47
15-18 years 18 40
Males 11-14 years 25 55
15-18 years 20 45
* Gradual decline with age

30. Dietary management
30
• A Healthy Eating Plan within your requirements gives your body the nutrients it needs
every day/ Emphasizes fruits, vegetables, whole grains, and fat-free or low-fat milk and
milk products Includes lean meats, poultry, fish, beans, eggs, and nuts Is low in saturated
fats, trans fat, cholesterol, salt (sodium), and added sugars.
• Controls portion sizes: Learn the difference between a portion and a serving and how to
keep portions reasonable.
• Educate the patient about the smart substitutions to reduce sodium, saturated fat and
added sugar.
• Eat regular meals & Don't let yourself get too hungry. This can help you to burn calories
at a faster rate and avoid becoming too hungry.
• The different studies shown : How we can support increase metabolic rate by consuming
some kind of foods ?

31. Conclusion
31
The evidence demonstrates that the majority of people
who lose weight regain much than of that weight over a period of
One to Five
years in the absence of continued intervention.
Any nutritionally balanced diet can be recommended …
but the focus should be on adherence to a diet that is individualized for medical
and metabolic conditions and ease of long-term maintenance and adherence.

32. Redustim
technology
Dr Daniel GREFF
PhD BioChemistry
PARIS - France

33. 5 critères d’évaluation du syndrome métabolique
The progressive destocking of lipids in excesses
situated at the abdominal level
Our target
pull a decrease of the waist measurement
so reduces the “health risks” connected to the metabolic syndrom

34. 5 critères d’évaluation du syndrome métabolique
ReduStim
spreads in the contact of the abdominal skin level
and to the global physical level …
Frequency 50 Hz
Our solution
… a low frequency alternating magnetic field
oscillating from o to 4 Gauss.
The magnetic field targets muscle cells
by activation of Ca++ ATPases of the sarcoplasmic reticulum (calcium pump)
and induces lipolysis of fat stored around the muscles.

35. 5 critères d’évaluation du syndrome métabolique
• Several international studies have demonstrated stimulation of ATPase membranes
associated with calcium in the presence of weak alternating magnetic fields, less than 5
Gauss (corresponding to those of REDUSTIM), at low frequencies from 40 to 60 Hz (50 Hz
for REDUSTIM).
• The Ca++ ATPase enzymes are localized in the membrane of the sarcoplasmic reticulum of
muscle cells where they account for 90% in weight of total membrane proteins.
• Sarcoplasmic reticulum stores calcium and the rapid flow of these ions from the
reticulum to the sarcoplasm (cytoplasm of muscle fibers) causes muscle contraction.
• The magnetic stimulation of the Ca++ ions that causes an increase in the activity of these
ATPase automatically entails stimulation of lipolysis of stored fat around the muscles,
without additional effort consumption.
• REDUSTIM therefore carries some of the energy expenditure cycle, as if a physical activity
was conducted.
Our scientific basis

36. 5 critères d’évaluation du syndrome métabolique
• Identification by DNA chip technology of the potential effects of 12
ReduStim sessions on gene expression in periphal blood of 11
individuals.
• The device has shown to induce a significant response, positively
modulating the expression of 89 genes in all the individuals in 73%
of cases and in parallel to the reduction of their waist
circumferences.
Our experimental proof

37. 37

38. 5 critères d’évaluation du syndrome métabolique
Activation of Ca++ ATPases
located in the membranes of the sarcoplasmic reticulum of muscle cells
by the alternating magnetic field low frequency.
Stimulation of the muscular contraction of smooth and skeletal muscles.
Leading a consumption of ATP energy
brought by a progressive destockage
of fat stored.
Our experimental proof

39. 5 critères d’évaluation du syndrome métabolique
MUSCULAR CELL (MYOCYTE)
ENERGY
Destocking lipids
Lipolysis
MYOFIBRILLE
CONTRACTE
D MUSCLE
RELAXED
MUSCLE
SARCOPLASMIC
RETICULUM
Sarcoplasmic
reticulum Sarcolemma
Mitochondrion
Nucleus
T-tubule
Myosin
Actin
Myosin Actin
Our experimental proof

40. Conclusion
40
The description of these various stages allows to release an exclusive mode
of action of the low frequency alternating magnetic fields.
The reduction of the excess of fat mass whether it is of abdominal or physical
nature, is obtained by a natural biological stimulation of the lipolysis and not by
an invasive and destructive process, without any side effect.
It is the reason why we use the term of "BIOMAGNETIC FIELD"
to define our technology.

41. 41

42. 42

43. 5 critères d’évaluation du syndrome métabolique
The progressive fat destockage
in excesses located
at the abdominal level.
pull a decrease of the waist measurement
reducing the
"health risks" connected to the metabolic
syndrom.
Our experimental proof

44. Non-invasive, non-aggressive
and totaly painless treatment ( 50 Hertz)
5 critères d’évaluation du syndrome métabolique
BIOMAGNETIC FIELDS
REDUSTIM
Non-ionising Ionising
Low induced
currents
Strong induced
currents
Electrical
excitation
Rupture of
molecular bonds
102 104 106 108 1010 1012 1014 1016 1018 1020
Radio Microwave Infrared Ultraviolet X-Ray
TV Cell phone UV lamp
Hz Frequency
Medical
X-ray
FM
Radio
AM
Radio
Electric
heaters
Home Power
lines
Our technology

45. Redustim, 100% hands-free medical device
45
ReduStim guarantees
visible results in
12 sessions and exists under 2
versions.
REDUSTIM
BioMagnetic field + Micropression
REDUSTIM SP
BioMagnetic field
Static
protocol
Dynamic
protocol
Static
protocol
Static
protocol

46. 5 critères d’évaluation du syndrome métaboliqueRedustim
BIOMAGNETIC
FIELD
+ MICROPRESSION

47. Redustim: Biomagnetic field + micropression
47
ReduStim takes the form of a device linked to an integral bodysuit
that covers a large part of the body, from the feet up to the solar
plexus. Two arms straps complete the device to diffuse the
BioMagnetic field for the aesthetic treatment of skin slackening in
this area.
It combines 2 simultaneous actions :
1. A main action based on the emission of BioMagnetic field to
stimulate the release of visceral fat.
2. A secondary action of controlled cutaneous micropressure
(drainage), facilitating body drain and the elimination of toxins.
Recommended treatment for overweight patients:
12 x 30 min sessions (2 sessions a week).
Recommended treatment for obese persons:
15 x 45 min sessions (2 sessions a week).

48. Global management of overweight and
abdominal obesity.
Infertility in obese persons.
Treatment of post-natal obesity.Metabolic syndrome as a factor of risk in
cardiovascular diseases and strokes.
Complementary medical methods: cryotherapy, infrared,
carboxytherapy, lasers...
Redustim: medical indications
48

49. 5 critères d’évaluation du syndrome métaboliqueRedustim SP, static protocol,
BIOMAGNETIC
FIELD

50. 5 critères d’évaluation du syndrome métaboliqueRedustim SP, dynamic protocol
BIOMAGNETIC
FIELD

51. 5 critères d’évaluation du syndrome métabolique
Dynamic protocol is preventing
cardiovascular risks. This protocol can
be used to optimise the results
combining the session with cardio
exercise.
REDUSTIM SP static protocol is realized with a
patient spread on a treatment table. A protocol
dedicated for people with reduced mobility and
having difficulties to exercise. It can be
supplemented with rolling massage, lymphatic
drainage or with other targeted medical methods.
Redustim SP: 2 protocols
Recommended treatment for overweight patients:
12 x 30 min sessions (2 sessions a week).
Recommended treatment for obese persons:
15 x 45 min sessions (2 sessions a week).

52. Redustim SP: medical indications
52
Global management of overweight and abdominal obesity.
Metabolic syndrome as a factor of risk in cardiovascular diseases and strokes.
Treatment of abdominal obesity in menopausal women.
37

53. Clinical studies
Dr Philippe BLANCHEMAISON
Angiologist – Phlebologist
PARIS - France

54. • A pivotal DNA chip study in 2009 proved the technology to
modulate intracellular Ca++ (Dr Benech).
• A double-blind clinical trial was meanwhile sponsored in the
metabolic syndrom indication (Dr Courie and Benichou, 2010)
with positive results.
• A clinical trial was sponsored in an indication suggested by the
study, infertility (Pr Frydman, 2011) with positive results.
• The visceral fat effects were confirmed in a scanner imaging
study (Dr Nouira and Carpentier, 2013).
Strong scientific background

55. A clinically recognized therapy supported by 10 scientific and clinical studies
1998: Dr. Fargeon (Paris – France) – sample of 42 female patients
2003: Dr. Karray (Paris – France) – sample of 203 female patients
2004: Dr. Cheibi (Tunis – Tunisia) – sample of 21 female patients
2006: Dr. Fargeon (Paris – France) – sample of 23 patients
2007: Dr. Pavie (Paris – France) – sample of 36 female patients
2008: Dr. Beilin (Paris – France) – sample of 22 female patients
1 pivotal DNA chips study
Scientific and Clinical studies
1
2
3
4
5
6

56. 56
7 2009: Dr Philippe Benech (Prediguard) : “DNA chips” based predictive
study on the physio-biological mode of action of Redustim
3 additionnal studies on BioMagnetic Field impact on health
2010: Dr Rodi Courie (Inserm U939 – Hospital Pitié Salpêtrière) – Dr
Florence Benichoux): randomized, double-blind clinical study. Average
waist loss of 6.1 cm after 12 sessions of Redustim
2011: Dr V. Gallot, Pr René Frydman, Pr R. Fanchin (Hôpital Antoine
Béclère – Clamart): clinical study on potential benefit of BioMagnetic
stimulation on Fertility: 55% pregnancy rate after 12 sessions of BMS (vs
23,7% in average)
2013: Dr Habib Nouira et Dr Bernadette Carpentier: scanner imaging
study: impact on the body fat content after 12 sessions
8
9
10

57. 347 patients observed in 6 different medically controlled studies
Waistline reduction of more than 1 size; no side-effect
1998 : Dr. Fargeon (Paris – France)
First study lead by Dr. Fargeon in 1998 to test effectiveness of Bodysculptor® on 42 overweight female patients. Results after 12
weeks showed an average decrease of the waist circumference by 6,1cm.
2003 : Dr. Karray (Paris – France)
Study lead by Dr Karray in 2003 on 203 female patients confirmed significant results on weight loss (average loss of 5,4 kg) and
waist circumference reduction: average loss of 10,5 cm.
2004 : Dr. Cheibi (Tunis – Tunisia)
Study lead by Dr Cheibi in 2004 on 21 female patients proved a reduction of more than 1 size for 100% of the patients after 12
sessions of 30 minutes and vibrating plate exercise (20 minutes).
Study 2006 : Dr. Fargeon (Paris – France)
4 Study lead by Dr Fargeon in 2006 on 23 female patients proved a reduction of more than 1 size for 100% of the patients after 12
sessions of 30 minutes and mechanical drainage (20 minutes).
2007 : Dr. Pavie (Paris – France)
Study lead by Dr Pavie in 2007 on 36 female patients proved a reduction of more than 1 size for 100% of the patients after 12
sessions of 30 minutes with micro-pressure stimulation.
2008 : Dr. Beilin (Paris – France)
Study lead by Dr Beilin in 2008 on 22 female patients proved a reduction of more than 1 size for 100% of the patients after 12
sessions of 30 minutes with micro-pression stimulation (3 sessions per week).
Study
1
Study
2
Study
3
Study
5
Study
6
Study
4
347 patients observed in 6 medical studies

58. Randomized, double-blind clinical study
Average reduction in waist measurement
Results in centimeters after 12 sessions
P<0,01*
* The significance level of the difference
is high: study carried out using Student’s
test on matched series.
Evaluation of average centimetre drop in waist
size in 28 patients with abdominal obesity after
12 sessions of ReduStim: -6.1 cm.
The other 4 metabolic syndrome criteria remain
unchanged.
The liver transaminase rate has reduced:
• ALAT:a 23% reduction
• ASAT:a 13% reduction
The circulating fatty acidsthat are released are
not stored in the liver:on the contrary,the
BioMagnetic field helps to detoxify it.
-6,07 Placebo
-1,81
Dr Rodi Courie (Inserm U939 – Hospital Pitié Salpêtrière) – Dr Florence Benichoux) - 2010
Study
8
Randomized, double-blind clinical study

59. Randomized, double-blind clinical study
59
Primary clinical result:
After a 12-session cure with Redustim®, average decrease in waist
circumference by 6,1 cm in patients with abdominal obesity vs -1,8 with
placebo.
The study demonstrated that the waist circumference decreased whereas the
4 other criteria of the metabolic syndrome haven’t been significantly modified
(which is a positive sign regarding the biological side effects of
the medical device).
Redustim® has a positive action on lipids accumulated abnormally around
visceral and muscles (mainly on the abdominal zone).

60. The results of the IVF in obese and overweight infertile female patients, after a
reduction of their waist circumference following 12 sessions of Redustim®.
38 female patients candidate for an IVF (first or second attempt) with a body
mass index (BMI) > 25 Kg/m2 has benefitted from 12 sessions of 30 minutes
Redustim® (with 2 sessions per week) during the 6 weeks preceding the ovarian
stimulation for the IVF, without any modification of the established clinical
protocol.
Dr V. Gallot, Pr René Frydman, Pr R. Fanchin (Hôpital Antoine Béclère – Clamart) - 2011
Study
9
Study
9
Study on fertility of overweight female patients

61. Randomized, double-blind clinical study
61
z
After a 12-session cure with Redustim®,
the clinical pregnancy rates after IVF,
in an obese infertile amount to 55.55%.
Classification BMI
No. of IV
Fertilization
patients
No. of
pregnancies
Pregnancy
rate
Overweight 25 to 29,9 11 4 36,36%
Class 1 obese 30 to 34,9 13 6 46,15%
Class 2 obese 35 to 39,9 8 5 62,50%
Class 3 obese
(morbid obesity)
40 over 6 4 66,67%
Total (all types) 25 to 40 over 38 19 50,00%
Total (obese only) 30 to 40 over 27 15 55,55%
Pregnancy rate in vitro fertilization as a
function of BMI
62,5%
46,15%
36,36%
66,67%
Overweight Class 1
obese
Class 2
obese
Class 3
obese

62. Dr Habib Nouira et Dr Bernadette Carpentier - 2013
The study using ReduStim SP in static mode quantified and compared the impact of the device after 12
sessions before and after treatment on sub- cutaneous and visceral body fat around the navel, using
Scanner view without preparation (Toshiba Aquilion 16).
This present study conducted on 20 volunteers (12 females + 8 males) with an average weight of 95.30 kg
and an average BMI of 30.90 has shown:
-An average reduction of 5.45 kg in weight and 6% in BMI
-An average reduction of 7 cmin waist circumference,8.2% in visceral body fat and 4.1% in sub-cutaneous
body fat
-An average reduction in transaminase ASATand ALATof 17.4% and 18% respectively
Scanner imaging study Study
10

63. Scanner imaging study
63
BEFORE
The technology proved to target in priority the visceral or “bad” fat and to a lesser extent
the subcutaneous fat (that happens to be an aesthetic concern but associated with a
lower morbidity). Released fatty acids are proved to be burnt by the organism and not
stocked in the liver.
AFTER

64. Redustim
results and testimonies
Dr Philippe BLANCHEMAISON
Angiologist – Phlebologist
PARIS - France

65. BEFORE AFTER BEFORE AFTER
BEFORE AFTER BEFORE AFTER
Before / after 12 Redustim sessions
65

66. Doctors equipped testimonials
66

67. Doctors equipped testimonials
67

68. Professional division portfolio: a Compelling Value Proposal for both
Customers and Practitioners
Our group has now equipped 2500 professional sites around the world. Each of them undergo 2 x 30’ sessions per
day on average or circa 600 per year (50 customers). Over 125,000 customers will use the technology this year and
more than 1,500,000 sessions will be managed. In cumulative terms it means over 15 billion sessions since 10 years.
With not one single serious side-effect reported, meaning a side-effect having led to an interruption of the protocol.
Efficacy on body shaping and good for health
The only device that works on
visceral/intra-abdominal fat
None-invasive and Safe with no side effects
No pain or risk of negative
metabolic interaction
Affordable pricing
The attractive economics of the
devices allow for average treatment prices
Value Proposal for the customer Value Proposal for the practitioner
Compelling risk/efficacy couple
Harmless, painful
with no side effects
(15 years “pharmaco-vigilance”)
Really hand-free
A session requires less than
10mn manipulation by the operator
Attractive Economics
Attractive ROI and short payback
(<1 year for more than 90% of the spas that were equipped)
No consumables or hidden costs
Devices values

69. A medical device that optimises global management of overweight or obese patients.
A device 100% Made in France with scientifically and clinically proven results.
A 100% hands-free treatment.
A device that improves the profitability of your medical center.
A device for recruiting new patients and also building loyalty
among your existing patients.
An alternative to major surgery (painless, non-invasive method).
A space saving device that does not require a dedicated cubicle.
Very few contraindications.
Devices strengths